Last Update: Aug 19, 2026 A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov Identifier: [NCT06655896](https://clinicaltrials.gov/ct2/show/NCT06655896) Novartis Reference Number:CYTB323K12201 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. This is a phase 2, multi-part, five-year, randomized, open-label, assessor-blinded, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse cutaneous systemic sclerosis (dcSSc). This study comprises two cohorts: \* A Lead-in Cohort enrolling participants to receive rapcabtagene autoleucel. \* A Randomized Cohort enrolling participants to receive rapcabtagene autoleucel or rituximab. Participants in the rituximab arm whose disease is not fully controlled may receive rapcabtagene autoleucel treatment once the participant is confirmed to be eligible per protocol. After end of study, participants who received rapcabtagene autoleucel infusion will enter a long-term follow-up (LTFU) period after rapcabtagene autoleucel infusion. This LTFU will be described in a separate study protocol. Condition Scleroderma, Diffuse Phase Phase2 Overall Status Recruiting Number of Participants96 Start Date Oct 29, 2024 Completion Date Aug 30, 2032 Gender All Age(s) 18 Years - 70 Years (Adult, Older Adult) ## Interventions Biological ### rapcabtagene autoleucel single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days. Biological ### rituximab rituximab intravenous infusion (i.v.) as per protocol ## Eligibility Criteria Inclusion Criteria: 1\. Participant must fulfill the 2013 American College of Rheumatology/ European League Against Rheumatism classification criteria for systemic sclerosis and meet the diffuse cutaneous SSc (dcSSc) subset classification according to LeRoy. 2\. Disease onset from the first non-Raynaud symptoms attributable to SSc (e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) within 7 years prior to the Screening visit. 3\. Severe, progressive systemic sclerosis disease defined by at least one of the following: \* Progressive systemic sclerosis-associated interstitial lung disease \* Severe, progressive systemic sclerosis skin disease \* Clinically significant systemic sclerosis-associated cardiac involvement at Screening 4\. All recommended vaccinations received according to institutional, local or global guidelines for immuno-compromised patients. Exclusion Criteria: 1\. Any condition during Screening that could prevent a complete washout of medications as required per protocol or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study, as judged by the Investigator. 2\. Participants with history of hypersensitivity to excipients in rapcabtagene autoleucel or to rituximab. 3\. Any participant for whom treatment with rituximab is clinically inappropriate in the opinion of the investigator. 4\. Any medical conditions that are not related to SSc that, in the opinion of the Investigator, would jeopardize the ability of the participant to tolerate lymphodepletion and anti-CD19 CAR-T cell therapy. 5\. Rheumatic disease other than dcSSc, (except secondary Sjogren's syndrome or scleroderma myopathy),including limited cutaneous systemic sclerosis (lcSSc) or sine scleroderma at Screening. 6\. Participants with pre-existing pulmonary hypertension. 7\. Significant renal pathology at Screening. 8\. Participants with uncontrolled stage II hypertension at Screening. 9\. Vaccination with live attenuated vaccines within 6 weeks prior to randomization. Other protocol-defined inclusion/exclusion criteria may apply. Argentina #### Novartis Investigative Site Recruiting CABA,C1181ach,Argentina #### Novartis Investigative Site Recruiting Córdoba,Córdoba Province,X5016keh,Argentina Australia #### Novartis Investigative Site Recruiting Darlinghurst,New South Wales,2010,Australia #### Novartis Investigative Site Recruiting Camperdown,New South Wales,2050,Australia Austria #### Novartis Investigative Site Recruiting Graz,8036,Austria #### Novartis Investigative Site Recruiting Vienna,1090,Austria #### Novartis Investigative Site Recruiting Vienna,1140,Austria Belgium #### Novartis Investigative Site Recruiting Ghent,9000,Belgium Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,01232-010,Brazil #### Novartis Investigative Site Recruiting Salvador,Estado de Bahia,41253-190,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,01308-050,Brazil #### Novartis Investigative Site Recruiting Curitiba,Paraná,80030-110,Brazil #### Novartis Investigative Site Recruiting Barretos,São Paulo,14784-400,Brazil Czechia #### Novartis Investigative Site Recruiting Olomouc,779 00,Czechia #### Novartis Investigative Site Recruiting Prague,128 00,Czechia Denmark #### Novartis Investigative Site Recruiting Aarhus N,8200,Denmark France #### Novartis Investigative Site Recruiting Montpellier,34295,France #### Novartis Investigative Site Recruiting Lyon,69003,France #### Novartis Investigative Site Recruiting Lille,59037,France #### Novartis Investigative Site Recruiting Paris,75014,France #### Novartis Investigative Site Recruiting Dijon,21000,France #### Novartis Investigative Site Recruiting Rennes,35033,France #### Novartis Investigative Site Recruiting Bordeaux,33076,France #### Novartis Investigative Site Recruiting Strasbourg,67091,France Germany #### Novartis Investigative Site Recruiting Berlin,13353,Germany #### Novartis Investigative Site Recruiting Leipzig,Saxony,04103,Germany #### Novartis Investigative Site Recruiting Jena,Thuringia,07740,Germany #### Novartis Investigative Site Recruiting Mainz,55131,Germany #### Novartis Investigative Site Recruiting Ulm,89081,Germany #### Novartis Investigative Site Recruiting Halle,Saxony-Anhalt,06120,Germany #### Novartis Investigative Site Recruiting Nuremberg,90419,Germany #### Novartis Investigative Site Recruiting Freiburg im Breisgau,Baden-Wurttemberg,79106,Germany #### Novartis Investigative Site Recruiting Göttingen,Lower Saxony,37075,Germany #### Novartis Investigative Site Recruiting Lübeck,23538,Germany Hungary #### Novartis Investigative Site Recruiting Debrecen,Hajdu Bihar Megye,4032,Hungary #### Novartis Investigative Site Recruiting Budapest,1083,Hungary Israel #### Novartis Investigative Site Recruiting Haifa,3109601,Israel #### Novartis Investigative Site Recruiting Tel Aviv,6423906,Israel #### Novartis Investigative Site Recruiting Ramat Gan,5265601,Israel Italy #### Novartis Investigative Site Recruiting Roma,RM,00168,Italy #### Novartis Investigative Site Recruiting Genova,GE,16132,Italy #### Novartis Investigative Site Recruiting Bergamo,BG,24127,Italy #### Novartis Investigative Site Recruiting Brescia,BS,25123,Italy #### Novartis Investigative Site Recruiting Pavia,PV,27100,Italy #### Novartis Investigative Site Recruiting Perugia,PG,06129,Italy #### Novartis Investigative Site Recruiting Udine,UD,33100,Italy #### Novartis Investigative Site Recruiting Milan,MI,20122,Italy #### Novartis Investigative Site Recruiting Milan,MI,20132,Italy #### Novartis Investigative Site Recruiting Pisa,PI,56126,Italy #### Novartis Investigative Site Recruiting Pescara,PE,65124,Italy #### Novartis Investigative Site Recruiting Ancona,AN,60020,Italy Japan #### Novartis Investigative Site Recruiting Sendai,Miyagi,9808574,Japan #### Novartis Investigative Site Recruiting Bunkyo-ku,Tokyo,113-8603,Japan #### Novartis Investigative Site Recruiting Fukuoka,8128582,Japan #### Novartis Investigative Site Recruiting Kyoto,6068507,Japan #### Novartis Investigative Site Recruiting Sapporo,Hokkaido,060-8648,Japan #### Novartis Investigative Site Recruiting Ishikawa,9208641,Japan #### Novartis Investigative Site Recruiting Suita,Osaka,5650871,Japan Mexico #### Novartis Investigative Site Recruiting Monterrey,Nuevo León,64460,Mexico Netherlands #### Novartis Investigative Site Recruiting Utrecht,3584 cx,Netherlands Singapore #### Novartis Investigative Site Recruiting Singapore,169608,Singapore South Korea #### Novartis Investigative Site Recruiting Seoul,06591,South Korea #### Novartis Investigative Site Recruiting Seoul,04763,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,06351,South Korea Spain #### Novartis Investigative Site Recruiting Barcelona,08041,Spain #### Novartis Investigative Site Recruiting Madrid,28041,Spain #### Novartis Investigative Site Recruiting Santander,Cantabria,39008,Spain #### Novartis Investigative Site Recruiting Pamplona,Navarre,31008,Spain #### Novartis Investigative Site Recruiting Córdoba,14004,Spain #### Novartis Investigative Site Recruiting Santiago Compostela,A Coruna,15706,Spain #### Novartis Investigative Site Recruiting Málaga,29010,Spain #### Novartis Investigative Site Recruiting Valencia,46026,Spain #### Novartis Investigative Site Recruiting Barcelona,08035,Spain #### Novartis Investigative Site Recruiting Madrid,28009,Spain #### Novartis Investigative Site Recruiting Salamanca,37007,Spain Switzerland #### Novartis Investigative Site Recruiting Lausanne,1011,Switzerland #### Novartis Investigative Site Recruiting Geneva,1211,Switzerland #### Novartis Investigative Site Recruiting Zurich,8091,Switzerland Taiwan #### Novartis Investigative Site Recruiting Taichung,407219,Taiwan United Kingdom #### Novartis Investigative Site Recruiting Sheffield,South Yorkshire,S10 2jf,United Kingdom United States #### University Of Iowa Recruiting Iowa City,Iowa,52242,United States ###### Darby Donovan Phone: [+1 319 356 2197]() Email: ###### Hanna Zembrzuska #### Northwestern University Recruiting Chicago,Illinois,60611,United States ###### Federica Sidoti Email: ###### George Georges #### UCSF Recruiting San Francisco,California,94115,United States ###### Emily Von Scheven ###### Zilan Zheng Phone: [+1 415 353 1301]() Email: ###### Zilan Zheng Phone: [+1 415 502 6627]() Email: #### Avera Cancer Recruiting Sioux Falls,South Dakota,57105,United States ###### Lauren Donelan Phone: [+1 605 322 3296]() Email: ###### Xavier Andrade-Gonzalez #### James Cancer Hospital Recruiting Columbus,Ohio,43210,United States ###### Ali Ajam ###### Claire Carlin Phone: [+1 614 293 3196]() Email: #### Oregon Health Sciences University Recruiting Portland,Oregon,97239,United States ###### Atul Deodhar ###### Issabell Melz Phone: [+1 503 494 9021]() Email: #### Sutter Health Network Recruiting San Pablo,California,94806,United States ###### Canary Jumawan Email: ###### Neftali Nevarez #### LDS Hospital Recruiting Salt Lake City,Utah,84143,United States ###### Catherine Jennifer Bakewell ###### Tara Sou Phone: [+1 801 408 1100]() Email: #### Boston Medical Center Recruiting Boston,Massachusetts,02118,United States ###### Marcin Trojanowski ###### Megha Sureka Phone: [+1 617 639 8760]() Email: #### UCLA Recruiting Los Angeles,California,90095,United States ###### Lauren Nam Email: ###### Suzanne Kafaja #### FL Medical Clinic Orlando Health Recruiting Zephyrhills,Florida,33542,United States ###### Julio Gonzalez-Paoli ###### William Daily Johnston Phone: [+1 813 782 1234]() Email: #### University of Minnesota Recruiting Minneapolis,Minnesota,55455,United States ###### Amanda DeGrote Email: ###### Hyun Kim #### Michigan Med University of Michigan Recruiting Ann Arbor,Michigan,48109-5271,United States ###### Aaron Burant Phone: [+1 734 615 4762]() Email: ###### Monalisa Ghosh ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: